Adult Dosing
Elevated intraocular pressure
- 1 gtt in affected eye(s) q12 hrs
Pediatric Dosing
- Safety and effectiveness in pediatric patients < 2 yrs have not been established
Elevated intraocular pressure
- 1 gtt in affected eye(s) q12 hrs
[Outline]
See Supplemental Patient Information
- Severe respiratory reactions, including death due to bronchospasm have occurred in patients with asthma on administration
- Provide sympathetic stimulation for support of circulation in individuals with diminished myocardial contractility. Severe failure has occurred on inhibition of sympathetic stimulation due to beta-adrenergic receptor blockade; cardiac failure has occurred on continuous depression of the myocardium over a period of time in patients without a history of cardiac failure. Discontinue therapy on signs and symptoms of cardiac failure
- Potentiation of syndromes associated with vascular insufficiency have occurred
- Severe anaphylactic reactions have occurred in patients with a history of atopy or history of severe anaphylactic reactions
- Potentiation of muscle weakness consistent with certain myasthenic symptoms
- Beta-adrenergic blockers may mask signs and symptoms of acute hypoglycemia
- Signs and symptoms of hyperthyroidism may be masked with beta-adrenergic blockers. Taper dose slowly as abrupt withdrawal may precipitate a thyroid storm
- Ocular hypersensitivity reactions associated with an increase in intraocular pressure have been reported with therapy
- Bacterial keratitis has occurred on use of multiple dose containers, which may be contaminated by patients having concurrent corneal disease or a disruption of the ocular epithelial surface
- Impairment of the ability of the heart to respond to beta-adrenergically mediated reflex stimuli has occurred. Risk of general anesthesia in surgical procedures may be potentiated, withdraw gradually before surgery
Cautions: Use cautiously in
- Coronary insufficiency
- Orthostatic hypotension
- Bronchospastic disease
- Chronic bronchitis
- Emphysema
- Depression
- Cerebral insufficiency
- Diabetes mellitus
- Spontaneous hypoglycemia
- Raynaud's phenomenon
- Thromboangiitis obliterans
- Peripheral vascular disease
- History of severe anaphylactic reaction
- Hyperthyroidism
- Myasthenia gravis
- Major surgery
- MAO Inhibitors
- Tricyclic Antidepressants
Supplemental Patient Information
- Avoid contamination of the container; avoid contacting the tip of dispensing container with the eye(s) or surrounding structures
- Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration
- If two or more drugs are used, administer at least five minutes apart
- Contact physician in case of ocular surgery or intercurrent ocular condition
- Patients who engage in hazardous activities should be cautioned about a decrease in mental alertness
Pregnancy Category:C
Breastfeeding: Safety unknown; maternal use of brimonidine 0.2% ophthalmic drops does not have an adverse affect on nursing infants. Timolol is excreted variably in breast milk; prefer other drugs especially while nursing a newborn or preterm infant. Ophthalmic use may pose little risk to the breastfed infant. To substantially diminish the amount of drug reaching the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more and remove the excess solution with an absorbent tissue. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 30 November 2010). Manufacturer advises caution, discontinue nursing, drug taking into account the importance of the drug to the mother
US Trade Name(s)
US Availability
Combigan (brimonidine/timolol)
Canadian Trade Name(s)
Canadian Availability
Combigan (brimonidine/timolol)
UK Trade Name(s)
UK Availability
Combigan (brimonidine/timolol)
Australian Trade Name(s)
Australian Availability
Combigan (brimonidine/timolol)
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- Combigan 0.2-0.5 % SOLN [Bottle] (ALLERGAN)
5 % = $90.85
15 % = $255.25
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.